SCHEMBL5095477

SCHEMBL5095477

CC(=O)c1ccc2nc(C)ccc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.55
RAB9A P51151 6/20 0.55
CYP1A2 P05177 3/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
CYP2A6 P11509 1/20 0.55
POLB P06746 2/20 0.52
KDM4E B2RXH2 2/20 0.52
LMNA P02545 2/20 0.52
CASP6 P55212 1/20 0.52
MAPT P10636 2/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
PIR O00625 2/20 0.45
BRAF P15056 1/20 0.45
HSF1 Q00613 1/20 0.45
KDM2B Q8NHM5 1/20 0.45
HTT P42858 1/20 0.44
VNN1 O95497 1/20 0.44
GUSB P08236 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31201668 1.00 NPC1 (0.55) NPC1RAB9ACYP1A2MEN1KMT2A
SCHEMBL9015187 0.87 CYP1A2 (0.53) NPC1RAB9ACYP1A2MEN1KMT2A
SCHEMBL999160 0.85 TDP1 (0.58) NPC1RAB9ACYP1A2MEN1KMT2A
SCHEMBL30464299 0.85 TDP1 (0.58) NPC1RAB9ACYP1A2MEN1KMT2A
SCHEMBL15286803 0.84 POLB (0.55) NPC1RAB9ACYP1A2MEN1KMT2A
SCHEMBL30163484 0.84 POLB (0.55) NPC1RAB9ACYP1A2MEN1KMT2A
SCHEMBL1000348 0.84 CYP1A2 (0.53) NPC1RAB9ACYP1A2MEN1KMT2A
Hydrochloric Acid SCHEMBL16621042 0.84 TDP1 (0.56) NPC1RAB9ACYP1A2MEN1KMT2A
Hydrochloric Acid SCHEMBL1000350 0.84 TDP1 (0.56) NPC1RAB9ACYP1A2MEN1KMT2A
SCHEMBL21241468 0.81 CYP1A2 (0.50) NPC1RAB9ACYP1A2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709725-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Progentos Therapeutics, Inc. (US) 2026-03-18 EP disclosed
CN-119019327-A Acetylation method of quinoline or isoquinoline compounds 常州工程职业技术学院 2024-11-26 CN disclosed
WO-2024233642-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PROGENTOS THERAPEUTICS, INC. (US) 2024-11-14 WO disclosed
US-20080207608-A1 2-Propene-1-Ones As Hsp 70 Inducers TORRENT PHARMACEUTICALS LTD. (IN) 2008-08-28 US disclosed
US-20080207608-A1 2-Propene-1-Ones As Hsp 70 Inducers TORRENT PHARMACEUTICALS LTD. (IN) 2008-08-28 US disclosed
US-20080207608-A1 2-Propene-1-Ones As Hsp 70 Inducers TORRENT PHARMACEUTICALS LTD. (IN) 2008-08-28 US disclosed
EP-1748987-A2 2-PROPENE-1-ONES AS HSP 70 INDUCERS Torrent Pharmaceuticals Ltd (IN) 2007-02-07 EP disclosed
WO-2005097746-A2 2-PROPENE-1-ONES AS HSP 70 INDUCERS TORRENT PHARMACEUTICALS LTD (IN) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207608-A1 2-Propene-1-Ones As Hsp 70 Inducers HSPB1, HSF1, HSPE1 NPC1 2567/4885RAB9A 1703/4885CYP1A2 801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.